Compugen Ltd.

Filed a patent for "il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer" on Mon, June 26, 2023

Filed a patent for "il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer" on Thu, July 27, 2023

Filed a patent for "il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer" on Fri, October 20, 2023

Filed a patent for "il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer" on Fri, December 8, 2023

Filed a patent for "triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab" on Mon, February 27, 2023

Filed a patent for "triple combination therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab" on Wed, March 8, 2023

Filed a patent for "il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer" on Fri, January 6, 2023

Filed a patent for "pvrl2 and/or pvrig as biomarkers for treatment" on Thu, March 28, 2024

Filed a patent for "combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies" on Thu, November 16, 2023

Filed a patent for "pvrl2 and/or pvrig as biomarkers for treatment" on Thu, December 14, 2023

Filed a patent for "anti-tigit antibodies, anti-pvrig antibodies and combinations thereof" on Thu, March 7, 2024

Filed a patent for "anti-pvrig antibodies formulations and uses thereof" on Thu, March 14, 2024

Filed a patent for "combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies" on Thu, December 1, 2022

Filed a patent for "anti-tigit antibody formulation" on Thu, May 26, 2022

Filed a patent for "combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies" on Mon, September 26, 2022